Metadata
- Name
- Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors
- Repository
- ClinicalTrials.gov
- Identifier
- clinicaltrials:NCT02401347
- Description
- The aim of this single-arm phase 2 clinical trial is to evaluate the anti-cancer activity of
Talazoparib (also known as BMN 673) in patients with advanced breast cancer with specific
genetic or tumor genomic alterations. Patients with either triple-negative or HER2-negative
breast cancer are eligible. - Data or Study Types
- clinical trial
- Keywords
- HRD assay score, PALB2 mutation, MRE11 mutation, BRIP1 mutation, Rad51d mutation, CHEK2 mutation, NBN mutation, BARD1 mutation, PTEN mutation, Rad50 mutation, ATR mutation, ATM mutation, Rad51c mutation, FANC mutation
- Source Organization
- Unknown
- Access Conditions
- available
- Year
- 2015
- Access Hyperlink
- https://clinicaltrials.gov/ct2/show/NCT02401347
Distributions
- Encoding Format: HTML ; URL: https://clinicaltrials.gov/ct2/show/results/NCT02401347